An Open Label, Randomized Phase 2 Trial of Prostvac and Ipilimumab as Monotherapy or in Combination for Men With Localized Prostate Cancer Undergoing Radical Prostatectomy
Phase of Trial: Phase II
Latest Information Update: 13 Jun 2017
At a glance
- Drugs Rilimogene galvacirepvec-rilimogene glafolivec (Primary) ; Ipilimumab
- Indications Prostate cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 06 Jun 2017 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.
- 06 Jun 2017 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.